David William Robbins

US Patent:

8106339, Jan 31, 2012

Filed:

Jun 26, 2007

Appl. No.:

11/821850

Inventors:

David William Robbins - Larsen WI, US
Scott W. Middleton - Oshkosh WI, US

Assignee:

Graphic Packaging International, Inc. - Marietta GA

International Classification:

H05B 6/80

US Classification:

219730

Abstract:

A construct for heating, browning, and/or crisping a food item in a microwave oven includes a panel having a first surface and a second surface opposite the first surface, a microwave energy interactive material overlying at least a portion of the first surface, wherein the microwave energy interactive material generates heat when exposed to microwave energy, and a thermally stable coating overlying at least a portion of the second surface.

US Patent:

8046171, Oct 25, 2011

Filed:

Apr 18, 2003

Appl. No.:

10/418514

Inventors:

David J. Ecker - Encinitas CA, US
Richard H. Griffey - Vista CA, US
Rangarajan Sampath - San Diego CA, US
Steven A. Hofstadler - Oceanside CA, US
John McNeil - La Jolla CA, US
Stanley T. Crooke - Carlsbad CA, US
Dino J. Sofianos - San Diego CA, US
Karl H. Rudnick - Solana Beach CA, US
Duane J. Knize - La Jolla CA, US
Roland B. Stoughton - San Diego CA, US
Clifford T. Lewis - San Diego CA, US
Brons M. Larson - Santee CA, US
Jonathan R. Bar-on - San Diego CA, US
Dennis P. Murray - Culver City CA, US
David W. Robbins - San Diego CA, US
John P. Penhune - La Jolla CA, US

Assignee:

Ibis Biosciences, Inc. - Carlsbad CA

International Classification:

G01N 33/50
G01N 24/00
B01D 59/44

US Classification:

702 19, 436173, 250281

Abstract:

Rapid and definitive bioagent detection and identification can be carried out without nucleic acid sequencing. Analysis of a variety of bioagents and samples, such as air, fluid, and body samples, can be carried out to provide information useful for industrial, medical, and environmental purposes. Nucleic acid samples of unknown or suspected bioagents may be collected, optimal primer pairs may be selected, and the nucleic acid may be amplified. Expected mass spectra signal models may be generated and selected, the actual mass spectra of the amplicons may be obtained. The expected mass spectra most closely correlating with the actual mass spectra may be determined using a joint maximum likelihood analysis, and base counts for the actual mass spectra and the expected mass spectra may be obtained. The most likely candidate bioagents may then be determined.

US Patent:

20120095696, Apr 19, 2012

Filed:

Sep 23, 2011

Appl. No.:

13/243912

Inventors:

David J. Ecker - Encinitas CA, US
Richard H. Griffey - Vista CA, US
Rangarajan Sampath - San Diego CA, US
Steven A. Hofstadler - Vista CA, US
John McNeil - La Jolla CA, US
Stanley T. Crooke - Carlsbad CA, US
Dino J. Sofianos - San Diego CA, US
Karl H. Rudnick - Solana Beach CA, US
Duane J. Knize - San Diego CA, US
Roland B. Stoughton - San Diego CA, US
Clifford T. Lewis - San Diego CA, US
Brons M. Larson - Santee CA, US
Jonathan R. Bar-on - San Diego CA, US
Dennis P. Murray - Culver City CA, US
David W. Robbins - San Diego CA, US
John P. Penhune - La Jolla CA, US

Assignee:

IBIS BIOSCIENCES, INC. - Carlsbad CA

International Classification:

G06F 19/22

US Classification:

702 20

Abstract:

Rapid and definitive bioagent detection and identification can be carried out without nucleic acid sequencing. Analysis of a variety of bioagents and samples, such as air, fluid, and body samples, can be carried out to provide information useful for industrial, medical, and environmental purposes. Nucleic acid samples of unknown or suspected bioagents may be collected, optimal primer pairs may be selected, and the nucleic acid may be amplified. Expected mass spectra signal models may be generated and selected, the actual mass spectra of the amplicons may be obtained. The expected mass spectra most closely correlating with the actual mass spectra may be determined using a joint maximum likelihood analysis, and base counts for the actual mass spectra and the expected mass spectra may be obtained. The most likely candidate bioagents may then be determined.

US Patent:

20140030232, Jan 30, 2014

Filed:

Aug 12, 2011

Appl. No.:

13/816723

Inventors:

Daniel Shoemaker - San Diego CA, US
Pratik Multani - San Diego CA, US
Caroline Desponts - San Diego CA, US
David L. Robbins - Temecula CA, US
Paul Grayson - La Jolla CA, US
John Mendlein - Encinitas CA, US

Assignee:

FATE THERAPEUTICS, INC. - San Diego CA

International Classification:

C12N 5/0789
A61K 35/28

US Classification:

424 937, 435375

Abstract:

The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of modified hematopoietic stem and/or progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic composition. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.

US Patent:

60870753, Jul 11, 2000

Filed:

Nov 7, 1997

Appl. No.:

8/966473

Inventors:

Edward J. Kler - Lakewood CA
David W. Robbins - Oxford CT
Robert R. Carey - Radnor PA

Assignee:

Label Systems, Inc. - Bridgeport CT

International Classification:

B42D 1500
B32B 706

US Classification:

430321

Abstract:

A tamper-evident label includes two parts that are separated from each other when an article to which they are attached is opened. The two parts have matching surface relief patterns secured to each other at an interface, and the indexes of refraction of the parts are substantially equal such that the patterns have no optical effect when attached to each other. When the two parts are separated, however, the patterns generate an image drawing attention to their separation. The patterns are preferably holographic.

US Patent:

20210340620, Nov 4, 2021

Filed:

Nov 12, 2020

Appl. No.:

17/096787

Inventors:

- San Diego CA, US
David L. Robbins - Temecula CA, US

International Classification:

C12Q 1/6876
A61K 35/28
C12Q 1/6881

Abstract:

The invention provides cell potency assays for measuring, determining, identifying, confirming, or validating the therapeutic potential of a cell population. Cell potency assays may be performed with various types of cells, including stem or progenitor cells, such as, for example, hematopoietic stem or progenitor cells. Cell potency assays may also be performed on stem or progenitor cells that have been treated with one or more agents to enhance therapeutic potential. Hematopoietic cells having therapeutic potential are useful in downstream clinical applications for increasing engraftment, reconstitution, homing, and proliferation in vivo.

US Patent:

20200339953, Oct 29, 2020

Filed:

May 11, 2020

Appl. No.:

16/872061

Inventors:

- San Diego CA, US
Pratik Multani - San Diego CA, US
Caroline Desponts - La Jolla CA, US
David L. Robbins - Temecula CA, US
Paul Grayson - La Jolla CA, US
John Mendlein - Encinitas CA, US

International Classification:

C12N 5/0789
A61K 35/28

Abstract:

The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of modified hematopoietic stem and/or progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic composition. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.

US Patent:

20200179451, Jun 11, 2020

Filed:

Jul 19, 2018

Appl. No.:

16/631781

Inventors:

- San Diego CA, US
- Seattle WA, US
Ian Hardy - San Diego CA, US
Betsy D. Rezner - San Diego CA, US
Christian Maine - San Diego CA, US
Daniel Shoemaker - San Diego CA, US
David Robbins - Temecula CA, US
Lucas Thompson - Seattle WA, US

International Classification:

A61K 35/17
A61K 45/06
A61P 35/00
C12N 5/0783

Abstract:

Compounds that either produce a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies, such as those providing improvements in one or more therapeutic outcomes, are provided.